CoChat
Sign Up
Cited by 232Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 82 of the 86 references it cites were found in a registry or an index.

Age as a Risk Factor for Stroke in Atrial Fibrillation Patients

Open access
Marinigh, Ricarda, Lip, Gregory Y.H., Fiotti, Nicola, Giansante, Carlo, Lane, Deirdre A.·2010·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2010.05.028
Open this paper in CoChat — free account

Abstract

The prevalence of atrial fibrillation (AF) is related to age and is projected to rise exponentially as the population ages and the prevalence of cardiovascular risk factors increases. The risk of ischemic stroke is significantly increased in AF patients, and there is evidence of a graded increased risk of stroke associated with advancing age. Oral anticoagulation (OAC) is far more effective than antiplatelet agents at reducing stroke risk in patients with AF. Therefore, increasing numbers of elderly patients are candidates for, and could benefit from, the use of anticoagulants. However, elderly people with AF are less likely to receive OAC therapy. This is mainly due to concerns about a higher risk of OAC-associated hemorrhage in the elderly population. Until recently, older patients were under-represented in randomized controlled trials of OAC versus placebo or antiplatelet therapy, and therefore the evidence base for the value of OAC in the elderly population was not known. However, analyses of the available trial data indicate that the expected net clinical benefit of warfarin therapy is highest among patients with the highest untreated risk for stroke, which includes the oldest age category. An important caveat with warfarin treatment is maintenance of a therapeutic international normalized ratio, regardless of the age of the patient, where time in therapeutic range should be > or =65%. Therefore, age alone should not prevent prescription of OAC in elderly patients, given an appropriate stroke and bleeding risk stratification.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.05.028

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 86 references

4 of the 86 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Feinberg, 1995, The prevalence of atrial fibrillation: analysis and implications, Arch Intern Med, 155, 469, 10.1001/archinte.1995.00430050045005 · DOI
  2. 1998, Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin, JAMA, 279, 1273, 10.1001/jama.279.16.1273 · DOI · Paper page

Cited by

Sorted by citations

Items 101–200 of 232

Related

See all

Metadata

Authors
Marinigh, R., Lip, G. Y. H., Fiotti, N., Giansante, C., & Lane, D. A.
Affiliations
  • University of Trieste (IT)
  • Birmingham City Hospital (GB)
Corresponding author
Lane, Deirdre A.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2010-09
Volume
56
Issue
11
Pages
827-837
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2010.05.028
OpenAlex
W152570996
Cited by
232
References
86
Citations by year
2026: 3 · 2025: 14 · 2024: 13 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 14 · 2019: 19 · 2018: 15 · 2017: 16 · 2016: 18 · 2015: 14 · 2014: 10 · 2013: 16 · 2012: 19
FWCI
3.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
Bayer Healthcare
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
atrial fibrillation, ischemic stroke, age as risk factor, oral anticoagulation, warfarin, antiplatelet therapy, bleeding risk, elderly patients, stroke risk stratification, time in therapeutic range, underrepresentation in clinical trials
MeSH terms
Age Factors, Atrial Fibrillation, Fibrinolytic Agents, Humans, Risk Factors, Treatment Outcome, Risk Assessment, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review